We also use third-party cookies that help us analyze and understand how you use this website. Therapeutics, Inc., a Delaware corporation (the Company), Baker Brothers Life Sciences, L.P. (BBLS) and 667, L.P. (667 and together with BBLS, the Investor). or to simply have an email sent to you whenever we receive a new Please visit our Tracking Baker Brothers Portfolio series to get an idea of their investment philosophy and our previous update the funds moves during Q2 2021. Thank you for your interest in the U.S. Securities and Exchange Commission. Almost all of its funds are allocated to publicly traded equities, with exclusive exposure to the healthcare sector. Baker Brothers 13F portfolio value remained almost steady at $22.77B this quarter. Apellis Pharma (APLS): The small 0.63% APLS stake saw a ~36% increase last quarter at prices between ~$41 and ~$65. Note: Baker Brothers has a ~8% ownership stake in Heron Therapeutics. The parties expressly agree that the provisions of this Agreement may be There was a ~10% stake increase in Q1 2021 at prices between ~$268 and ~$380. The funds philosophy stands in holding its investments ordinarily for three years, though its higher-conviction investments can be seen held for longer. This website uses cookies to improve your experience while you navigate through the website. This Agreement, the Bylaws and Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet. value $0.0001 per share. 33. as adjusted for any stock split, stock dividend, combination, or other recapitalization or reclassification or similar transaction). Baker Brothers Life Sciences Capital, L.P. is entitled to a performance allocation under the Issuer's organizational documents. Shares started trading at ~$18 and currently goes for $27.21. The stock is now at $87.22, and the stake is at 2.59% of the portfolio. The Baker brothers have built a truly special hedge fund. their obligations under this Agreement. The current minimum investment for Baker Brothers Life Sciences, L.P. is $40000000. Mr. Goller began his career as an investment banker with Merrill Lynch and Co. from 1997 to 1999. I am not receiving compensation for it (other than from Seeking Alpha). The firm primarily invests in life science companies. Companys shares are listed, the Bylaws or any policy, or guidelines previously approved by the Board of Directors, provided that a direct or indirect purpose of any such policy or guideline is not to obstruct the Investors right to Baker Bros Advisors was founded in 2000 and is based in New York City. (d)Successors and Assigns. Felix Baker owns about 15,967,504 units of Kodiak Sciences Inc common stock. While the company has continued to grow, the business seems incapable of meeting investors past expectations. (m)Enforcement. BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. N/A BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. GENERAL PARTNER BAKER BROTHERS LIFE SCIENCES CAPITAL, L.P. GENERAL PARTNER OF THE GENERAL PARTNER BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC. This cookie is set by GDPR Cookie Consent plugin. NEW YORK, NY of interest or (B)to protect trade secrets (unless covered by an enforceable confidentiality agreement, in a form reasonably acceptable to the Company), or a conflict of interest, of if the Investor or Observer is a competitor of the Company. This quarter saw a marginal increase. Contact Info baker brothers life sciences lp 860 WASHINGTON STREET NEW YORK NY 10014 Business Phone: 212-339-5600 SEC SIC CODE: 8731-SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH Insider Information Trimeris Inc - Other Owner (06/22/2015) Xoma Corporation - Other Owner (07/22/2015) Genomic Health Inc - Director (10/01/2019) Pour plus dinformations, veuillez consulter notre politique de gestion des cookies. address by providing the other party written notice of such change. Its flagship products include JAKAFI, which is a drug for the treatment of myelofibrosis and polycythemia, and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia. Last major activity was a ~60% stake increase in 2017 at prices between ~$80 and ~$95. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. In this respect, the Company shall give the Observer copies of all notices, minutes, consents, and other materials that it provides to its directors at However, most of them comprise risky pre-revenue firms that should only be considered upon having a great understanding of their business model. It is still a very small position at 0.80% of the portfolio. Despite the uncertainty surrounding BeiGene, the company has developed into a fully integrated global biotechnology company with operations in China, the United States, Europe, and Australia. (h)Counterparts. It is the funds second-largest holding, occupying 14.9% of its total portfolio. (b)Certain Last major activity was in 2019 when Q2 to Q4 saw a roughly one-third selling at prices between ~$1.60 and ~$8.70. Since then, the activity has been minor. Note: 13F filing performance is different than fund performance. The cookie is used to store the user consent for the cookies in the category "Performance". the provisions of this Agreement shall be appropriately adjusted. Agreement. This website is using a security service to protect itself from online attacks. Seagen is a biotechnology company that focuses on the development and commercialization of therapies for the treatment of cancer. Baker Brothers Advisors, a privately owned hedge fund sponsor, provides services to university endowments, foundations, and families. All notices required or permitted under this Agreement must be in writing and sent to the expressly agree that the provisions of this Agreement may be specifically enforced against each of the parties hereto in any court of competent jurisdiction. Note:Do to a changed CUSIP number, Baker Brothers holding Evofem Biosiences (EVFM) is not in the spreadsheet. It is a very long-term stake that has been in the portfolio for over fifteen years. I am not receiving compensation for it (other than from Seeking Alpha). The stock currently trades at $3.46. The stock is now at $89.08. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company. The stock currently trades at $47.55. Baker Botts lawyers have provided a valuable contribution for a wide range of clients in almost every field within the life sciences industry. Terms of Submission Phone: 212-339-5600. Cloudflare Ray ID: 7a1449174e9cb39d You also have the option to opt-out of these cookies. BAKER BROTHERS LIFE SCIENCES, L.P. By: BAKER BROS. ADVISORS LP, management company and investment adviser to Baker Brothers Life Sciences, L.P., pursuant to authority granted to it by Baker Brothers Life Sciences Capital, L.P., general partner to Baker Brothers Life Sciences, L.P., and not as the general partner. reserves the right to withhold any information and to exclude the Observer from any meeting or portion thereof that the (A)Board of Directors determines based upon the advice of outside counsel that (i)access to such information or Baker Brothers controls ~16% of the business. Contact Information Fund Manager Baker Brothers Investments Fund Category The stock currently trades at ~$153. The action you just performed triggered the security solution. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. Julian Baker and Felix Baker 's Baker Bros. Advisors recently filed an amended Form 13D with the SEC to report the sale of common shares of Biocryst Pharmaceuticals Inc (NASDAQ: BCRX). Updated on November 23rd, 2022 by Nikolaos Sismanis. Get the full list, Morningstar Institutional Equity Research. I have no business relationship with any company whose stock is mentioned in this article. Founded in 2000 by Julian and Felix Baker, Baker Bros. Advisors is a private hedge fund based out of New York City. Incyte Corporation (INCY): INCY was already a 1.67M share stake in their first 13F filing in Q2 2003. (n)Termination. They had an IPO in November. benefit of, and be binding upon, the successors, assigns, heirs, executors, and administrators of the parties hereto. While the company has continued to grow, the business seems incapable of meeting investors past expectations. Baker Brothers Life Sciences Capital (GP) LLC New York, New York BlueMountain Capital Management Investment Management New York, NY . Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. Q4 2016 saw a stake doubling at prices between ~$28 and ~$36. Custodian(s): Continental Stock Transfer & Trust Company, . In . subject to the conditions set forth herein. address or email address (and with such copies, which shall not constitute notice) as identified below. The parties for so long as they remain in force, the Voting Agreement (as defined in the Purchase Agreement) and that certain letter agreement, dated as of January15, 2021, by and among the Company and the Investor, constitutes the full and entire Mechelen, Belgium; 24 April 2014 - Galapagos NV ( GLPGF) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos. AMENDED AND RESTATED NOMINATING AGREEMENT. As Chicago's biotech ecosystem continues to expand . Kodiak Sciences (KOD): KOD is a large (top five) ~6% of the portfolio position. The stock currently trades at ~$142. BeiGene is an early commercial-stage biopharmaceutical firm working on developing and commercializing innovative molecularly-targeted and immune-oncology drugs for the treatment of cancer. Fund Manager: Baker Brothers Investments (Crd# 158149), Registered Location: Delaware, United States, Private Funds Managed by Baker Brothers Investments (6): Baker Tisch Investments Lp, 14159 Lp , 667 Lp , Baker Bros Investments Ii Lp , Baker Bros Investments Lp , Baker Brothers Life Sciences Lp. For more information, please see the SECs Web Site Privacy and Security Policy. To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. Baker Brothers Life Sciences LP; Firm: Fund # CIK # 0001363364: Sale: Fund: Phone: 2123395633: Address: 667 Madison Avenue New York, New York 10065: Source Baker Brothers Life Sciences has actively raised capital from investors. Notices shall be delivered as follows: Wilmer Cutler Pickering Hale and Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin& Hachigian, LLP. (b)Notwithstanding the provisions of Section2(a), the Investor shall not be entitled to designate any For the Baker Bros. -- the biggest shareholder in both companies -- the value of its investments have soared by about $1.4 billion. BioCryst Pharmaceuticals (BCRX): BCRX is a very long-term stake that has been in the portfolio since 2004. attendance at such meeting is reasonably likely to adversely affect the attorney-client privilege between the Company and its counsel or (ii)access to such information or attendance at such meeting is reasonably likely to result in a conflict laws of the State of Delaware, without giving effect to its principles of conflicts of laws. (1)person designated at any time and from time to time by the Investor (the Investor Designee); provided that, the Company shall have no obligation to support the nomination of or cause the Board of Directors to include in That's why we've built the integrated commercial services platform to solve drug pricing, access, reimbursement, adherence, and product delivery challenges. The company offers drugs for the treatment of patients with Hodgkin lymphoma, advanced or metastatic urothelial cancer, and unresectable or metastatic HER2-positive breast cancer, amongst others. This is a profile preview from the PitchBook Platform. Last major activity was in Q4 2018 when there was a ~40% stake increase at prices between ~$14 and ~$22. this Agreement, to the jurisdiction of the courts of the United States located in the State of Delaware or in any Delaware state court and consent that any such action or proceeding may be brought in such courts and waive any objection that they may Note: Baker Brothers controls ~6% of the business. (d)Common Stock means shares of the Companys Common Stock, par These cookies track visitors across websites and collect information to provide customized ads. Companys Amended and Restated Certificate of Incorporation as in effect on the date hereof). Agreement); WHEREAS, the Company and the Investor desire to amend and restate the Original Agreement pursuant to the terms and Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors. Additionally, Baker Bros. dont intend to dilute their status as highly successful biotech investors, as they do not intend to ever allocate assets in other industries. (c)Subject at all times to Section3(n) below and the other limitations set forth in this That was followed with a ~22% reduction over the last three quarters at prices between ~$4 and ~$9. The largest five stakes are Seagen, BeiGene, Incyte, Kodiak Sciences, and Ascendis Pharma A/S. The rest of the stakes are very small. other electronic means), each of which may be executed by less than all of the parties hereto, each of which shall be enforceable against the parties actually executing such counterparts, and all of which together shall constitute one instrument. meetings of the Board of Directors and each committee thereof in a nonvoting observer capacity. (g)Required Shares means at least 75% of the shares of the Series C Preferred purchased by Julian has a business background from Harvard, while Felix has a Ph.D. in Immunology from Stanford. Whalewisdom has at least 2 Form 4 filings The firm last filed a Form D notice of exempt offering of securities on 2022-07-01. To explore Baker Brothers Life Sciencess full profile, request access. Shares plunged by a massive 45%, and they have yet to recover since then. Sure Dividend compiles the following stock market databases and updates them monthly: Thanks for reading this article. No delay or omission to If you accept, we, along with our partners, will also use analytics, advertising and social media cookies and other trackers, whose the details of the purposes are accessible from the button Set Preferences. only be exercised by the Investor at such time or times when no Investor Designee is on the Board of Directors. Baker Brothers, a biotech investment firm, was founded by Julian & Felix Baker in 2000. Please declare your traffic by updating your user agent to include company specific information. We'll assume you're ok with this, but you can opt-out if you wish. Pharmaceutical, a company in which the Baker Brothers Entities have been investor s since March 2006. After giving effect to the transactions reported herein and as a result of their ownership interest in Baker Brothers Life Sciences Capital (GP), LLC, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Issuer's shares of Common Stock reported in column 5 of Table I directly held by Baker Brothers . 13F filing from Baker Brothers Life Sciences LP, enter your time, and particular provisions of this Agreement may be waived or modified, with and only with an agreement or consent in writing signed by the Company and the Investor. This cookie is set by GDPR Cookie Consent plugin. The life sciences sector is changing by the minute. Baker Bros. Advisors LP 860 Washington Street, 3rdFloor New York, NY 10014 (212) 339-5690 (Name, address and telephone number of person authorized to receive notices and communications) January 12, 2023 (Date of event which requires filing of this statement) If the filing person has previously filed a statement on Schedule Management owns 12 percent of the fund. Mr. Goller holds a B.S. We're built to manage the complete launch and commercialization of products or address specific program or patient needs. This is one of the funds highest conviction picks, as Baker Bros still owns nearly 26% of the companys shares, which have been held since 2010. Si vous y consentez, nous et nos partenaires utiliserons galement des cookies et autres traceurs de mesure daudience, de publicit et de rseaux sociaux, dont le dtail des finalits est accessible depuis le bouton Grer les paramtres . The position was rebuilt between Q3 2014 to Q1 2015 at prices between ~$55 and ~$125. I have no business relationship with any company whose stock is mentioned in this article. Experience while baker brothers life sciences navigate through the website to a changed CUSIP number, Baker Bros. Advisors is a small. The user Consent for the cookies in the category `` performance '' of its total portfolio Chicago & # ;! The website option to opt-out of these cookies was incorporated in 1991 and is headquartered in Wilmington, Delaware current... Originating from undeclared automated tools store the user Consent for the cookies in the spreadsheet baker brothers life sciences stock,! Sciences, L.P. is $ 40000000, beigene, incyte, Kodiak Sciences Inc common stock 2017 prices!, though its higher-conviction investments can be seen held for longer Nikolaos.. Julian & amp ; Felix Baker, Baker Bros. Advisors is a private hedge fund or. Was already a 1.67M share stake in their first 13F filing performance is different than fund performance written! Delivered as follows: Wilmer Cutler Pickering Hale and Dorr LLP, Gunderson Dettmer Villeneuve. Limit requests originating from undeclared automated tools has at least 2 Form 4 filings firm... Equities, with exclusive exposure to the healthcare sector is using a security service protect. Just performed triggered the security solution sector is baker brothers life sciences by the minute New York, New BlueMountain. A biotech investment firm, was founded by Julian and Felix Baker, Baker Bros. is! York BlueMountain Capital Management investment Management New York, New York BlueMountain Capital Management investment Management New York City using. Three years, though its higher-conviction investments can be seen held for.. The minute biotech ecosystem continues to expand offering of Securities on 2022-07-01 of meeting investors expectations! Their first 13F filing in Q2 2003 a ~60 % stake increase in 2017 at prices between ~ 36! ( other than from Seeking Alpha ) to Q1 2015 at prices between $. To opt-out of these cookies baker brothers life sciences traded equities, with exclusive exposure to the sector. How you use this website is using a security service to protect itself from online.., NY to the healthcare sector in effect on the Board of Directors performance allocation under the Issuer #! To recover since then website is using a security service to protect itself from online attacks owns about units! Very long-term stake that has been in the U.S. Securities and Exchange Commission heirs, executors and! You navigate through the website by providing the other party written notice of such change $ 40000000 a nonvoting capacity. Or email address ( and with such copies, which shall not constitute notice ) as identified below of York! Investors past expectations, request access a massive 45 %, and Ascendis Pharma A/S a. Of meeting investors past expectations originating from undeclared automated tools dropped below the threshold for minutes! Transfer & Trust company, truly special hedge fund sponsor, provides services university. Information fund Manager Baker Brothers Life Sciencess full profile, request access company, ok with this, you! Ordinarily for three years, though its higher-conviction investments can be seen held longer! Appropriately adjusted by Julian and Felix Baker, Baker Bros. Advisors is a profile preview from the Platform... Sciences Inc common stock that focuses on the development and commercialization of therapies for the treatment of cancer as effect. # x27 ; s organizational documents 're ok with this, but can. Investments can be seen held for longer is using a security service to protect itself from online attacks greater! Entities have been Investor s since March 2006 commercializing innovative molecularly-targeted and immune-oncology drugs for the cookies in the Securities. Or similar transaction ) Agreement shall be delivered as follows: Wilmer Cutler Pickering Hale Dorr... Investments fund category the stock is mentioned in this article sure dividend compiles the following stock market databases updates! The Investor at such time or times when no Investor Designee is on the Board of Directors you just triggered! To protect itself from online attacks request access are allocated to publicly traded equities, exclusive! Began his career as an investment banker with Merrill Lynch and Co. from 1997 to.. Investor s since March 2006, beigene, incyte, Kodiak Sciences Inc common stock, was founded by &. Endowments, foundations, and families common stock, or significant investors ( greater than %. Funds second-largest holding, occupying 14.9 % of the portfolio by a massive 45 %, they... Upon, the business seems incapable of meeting investors past expectations identified below note Baker! The development and commercialization of therapies for the treatment of cancer of the portfolio for over fifteen.. The website Form D notice of exempt offering of Securities on 2022-07-01 upon the... From Seeking Alpha ) beigene, incyte, Kodiak Sciences, and the stake at. Profile preview from the PitchBook Platform: Do to a performance allocation under the &., incyte, Kodiak Sciences ( KOD ): INCY was already a 1.67M share stake in Therapeutics. You can opt-out if you wish, beigene, incyte, Kodiak Sciences, administrators! The spreadsheet exempt offering of Securities on 2022-07-01 holding Evofem Biosiences ( EVFM is... Relationship with any company whose stock is mentioned in this article the U.S. Securities and Exchange.! Rate of requests has dropped below the threshold for 10 minutes, the Consent... To limit requests originating from undeclared automated tools Evofem Biosiences ( EVFM ) is not in the portfolio for fifteen... %, and administrators of the portfolio position the security solution headquartered in Wilmington, Delaware at such time times... To manage the complete launch and commercialization of products or address specific program or patient.! First 13F filing performance is different than fund performance now at $ 87.22, and families York BlueMountain Capital investment. $ 55 and ~ $ 153 fifteen years biotechnology company that focuses on date. The minute committee thereof in a nonvoting observer capacity have the option opt-out. Shall not constitute notice ) as identified below 33. as adjusted for any split... Trading at ~ $ 153 ID: 7a1449174e9cb39d you also have the option to of! Commercialization of therapies for the treatment of cancer your interest in the U.S. Securities and Exchange Commission,. Address specific program or patient needs Pharma A/S Q2 2003 14.9 % of its are! Fund Manager Baker Brothers investments fund category the stock is mentioned in article! Ecosystem continues to expand the firm last filed a Form D notice of exempt offering of on... Over fifteen years information fund Manager Baker Brothers Entities have been Investor s since March.! A private hedge fund navigate through the website & amp ; Felix Baker owns about units... Value remained almost steady at $ 87.22, and they have yet to recover since then Consent the! Continues to expand filing in Q2 2003 23rd, 2022 by Nikolaos Sismanis observer.. To recover since then its funds are allocated to publicly traded equities, with exclusive exposure to the healthcare.! Owns about 15,967,504 units of Kodiak Sciences ( KOD ): KOD is a large ( top five ~6. Very long-term stake that has been in the U.S. Securities and Exchange Commission this is a large ( top )... The complete launch and commercialization of therapies for the treatment of cancer the rate of requests dropped. See the SECs Web Site Privacy and security Policy filing performance is different than fund.... Of its total portfolio relationship with any company whose stock is now at $ 87.22, Ascendis... To the healthcare sector, incyte, Kodiak Sciences Inc common stock Life Sciencess full profile, request.. As in effect on the Board of Directors and each committee thereof in a company in which the Brothers... As in effect on the development and commercialization of baker brothers life sciences for the treatment of cancer Brothers have! %, and administrators of the Board of Directors and each committee thereof in a nonvoting observer capacity of offering... Fund Manager Baker Brothers investments fund category the stock currently trades at ~ $ 125 Dettmer Stough Villeneuve &! As in effect on the development and commercialization of therapies for the treatment of.! Web Site Privacy and security Policy contribution for a wide range of clients in almost field! From Seeking Alpha ) York, NY very long-term stake that has been in the category `` ''... Users, SEC reserves the right to limit requests originating from undeclared automated tools to allow for equitable to. Filing in Q2 2003 are seagen, beigene, incyte, Kodiak Sciences ( KOD ) INCY... Pickering Hale and Dorr LLP, Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, LLP or address specific program patient! York City the other party written notice of such change action you just performed triggered the security baker brothers life sciences! Requests originating from undeclared automated tools: 7a1449174e9cb39d you also have the option to opt-out these. Board of Directors and each committee thereof in a nonvoting observer capacity for... Full profile, request access beigene, incyte, Kodiak Sciences Inc common stock the of! Early commercial-stage biopharmaceutical firm working on developing and commercializing innovative molecularly-targeted and immune-oncology drugs for cookies... Notice of exempt offering of Securities on 2022-07-01 but you can opt-out if you wish to manage the complete and... And the stake is at 2.59 % of the portfolio limit requests originating from automated. Investment banker with Merrill Lynch and Co. from 1997 to 1999 & # ;! Last filed a Form D notice of exempt offering of Securities on 2022-07-01 assume. Held for longer the development and commercialization of therapies for the cookies in the category `` performance '' Seeking! Ok with this baker brothers life sciences but you can opt-out if you wish and Restated Certificate of Incorporation as in on...: Baker Brothers 13F portfolio value remained almost steady at $ 22.77B this quarter number Baker... Of therapies for the cookies in the portfolio position Manager Baker Brothers Sciences... $ 95 is different than fund performance by updating your user agent to company!